Tara A. Schwetz (born Tara Ashley Munn; May 4, 1983) is an American biophysicist and government administrator who serves as a deputy director of the National Institutes of Health. She previously served as Acting Principal Deputy Director.[1][2]
Prior to her appointment as Acting Principal Deputy Director, she served as the Associate Deputy Director, NIH—a role she has held began in January 2019.[3]
A native of Lakeland, Florida, Schwetz is a first-generation college graduate. Schwetz received a Bachelor of Science in Biochemistry with honors from Florida State University in 2005 (Honors Thesis: Non-metal activation of iron-dependent regulator protein in mycobacterium tuberculosis). She then went on to earn a Doctor of Philosophy in Medical Sciences, Biophysics from the University of South Florida in 2009 (Dissertation: Glycosylation Modulates Cardiac Excitability by Altering Voltage-Gated Potassium Currents[4]). Schwetz was a postdoctoral researcher in the lab of David W. PistonatVanderbilt University from 2009 to 2012.[5]
Throughout her nearly decade-long career at the NIH, Schwetz has held multiple positions, both within the Office of the Director and across several Institutes.
Her former roles include Chief of the Strategic Planning and Evaluation Branch at the National Institute of Allergy and Infectious Diseases, where she led several efforts, including an evaluation of the Centers of Excellence for Influenza Research and Surveillance[7] to facilitate evidence-based decision-making and development of the NIAID Strategic Plan for Tuberculosis Research.[8][9] Schwetz also served as the Senior Advisor to the Principal Deputy Director of NIH, the NIH Environmental influences on Child Health Outcomes (ECHO)[10] Interim Associate Program Director,[11] and as a Health Science Policy Analyst at the National Institute of Neurological Disorders and Stroke. Schwetz started her career at NIH as an AAAS Science and Technology Policy Fellow at NINR.
Schwetz has led or co-led a number of high-profile, agency-wide efforts, including two Rapid Acceleration of Diagnostics (RADx)[12] programs (RADx Underserved Populations,[13] RADx Radical[14])[15][16] to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing, and the Implementing a Maternal health and Pregnancy Outcomes Vision for Everyone (IMPROVE)[17][18] initiative. She also spearheaded several strategic planning efforts, such as the first NIH-Wide Strategic Plan and the NIH-Wide COVID-19 Strategic Plan;[19][20][21] and played a significant role in the development of the National Pain Strategy.[22][23][24]
For much of 2021, Schwetz served on detail to the White House Office of Science and Technology Policy as the Assistant Director for Biomedical Science Initiatives.[25] In this role, she led development and planning efforts to stand up the proposed Advanced Research Projects Agency for Health (ARPA-H).[26][27][28][29] The Biden Administration proposed ARPA-H in the fiscal year 2022 President’s budget request[30] to tackle some of the biggest health challenges faced by all Americans by driving medical innovation more rapidly.
^"RADx". National Institutes of Health (NIH). Retrieved 2022-01-06.
^"RADx Programs". National Institutes of Health (NIH). 2020-06-23. Retrieved 2022-01-06.
^"RADx Programs". National Institutes of Health (NIH). 2020-06-23. Retrieved 2022-01-06.
^Riley WT, Borja SE, Hooper MW, Lei M, Spotts EL, Phillips JRW, Gordon JA, Hodes RJ, Lauer MS, Schwetz TA, Pérez-Stable E. E. Transl Behav Med. 2020 Oct 8;10(4):857-861.
